SCHEMBL3029679

SCHEMBL3029679

FCCNc1ccc(Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
APP P05067 3/20 0.46
MAPT P10636 3/20 0.42
HDAC1 Q13547 1/20 0.42
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
NPC1 O15118 1/20 0.41
RECQL P46063 1/20 0.41
RAB9A P51151 1/20 0.41
GAA P10253 3/20 0.41
RHOC P08134 2/20 0.41
RHOA P61586 2/20 0.41
ALDH1A1 P00352 2/20 0.40
LMNA P02545 1/20 0.40
CYP2A6 P11509 1/20 0.40
CYP2D6 P10635 1/20 0.40
HPGD P15428 1/20 0.40
GFER P55789 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9639726 0.87 MAPT (0.55) MEN1KMT2AMAPTHDAC1CYP1A2
SCHEMBL656024 0.83 STK17A (0.50) MEN1KMT2AMAPTCYP1A2CYP2C9
SCHEMBL28876980 0.82 MEN1 (0.48) MEN1KMT2AMAPTHDAC1CYP1A2
Hydrochloric Acid SCHEMBL28709080 0.81 STK17A (0.49) MEN1KMT2AMAPTCYP1A2CYP2C9
SCHEMBL1947326 0.80 MEN1 (0.47) MEN1KMT2AMAPTHDAC1CYP1A2
SCHEMBL11348193 0.79 STK17A (0.55) MEN1KMT2AMAPTRHOCRHOA
SCHEMBL296404 0.78 HPGD (0.46) MEN1KMT2AMAPTHDAC1NPC1
SCHEMBL423851 0.78 MEN1 (0.46) MEN1KMT2AMAPTHDAC1CYP1A2
SCHEMBL4155501 0.78 MEN1 (0.46) MEN1KMT2AMAPTHDAC1CYP1A2
SCHEMBL1801536 0.78 NR1I2 (0.56) MEN1KMT2AMAPTCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100210617-A1 Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2010-08-19 US disclosed
EP-1904451-A1 ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS Astex Therapeutics Limited (GB) 2008-04-02 EP disclosed
WO-2006136830-A1 ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210617-A1 Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors ERBB2, ABL1, GRK2 MEN1 2076/4885KMT2A 26/4885APP 3026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.